New trial aims to improve survival for a tough pancreatic cancer

NCT ID NCT07155629

Not yet recruiting Disease control Sponsor: Helsinki University Central Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 3 trial will test whether giving chemotherapy before surgery helps people with resectable left-sided pancreatic cancer live longer compared to surgery alone. About 381 participants will be randomly assigned to either neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) followed by surgery, or upfront surgery. The study aims to fill a gap in evidence for this specific tumor location.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mFOLFIRINOX or nab-paclitaxel plus gemcitabine chemotherapy
What this could lead to: If it works, this could show that giving chemotherapy before surgery helps people with left-sided pancreatic cancer live longer.
What could go wrong: This is a phase 3 trial, but results are not yet available. Chemotherapy has side effects, and it may not improve survival compared to surgery alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER RESECTABLE

Contacts and locations

Locations

Helsinki University Central Hospital

Helsinki, 00290, Finland
Oulu University Hospital

Oulu, 90220, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.